MedTrace Logo

Disruption of Memory Reconsolidating as a Treatment for Panic Disorder

NCT02631694 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-12-16

No results posted yet for this study

Summary

Animal and human fear conditioning studies have repeatedly shown that administering propranolol before or after retrieval of a previously acquired fear results in an elimination of the fear expression. This approach, known as disruption of fear memory reconsolidation, is a promising new avenue for treating anxiety disorders. The present study aims to test its efficacy in patients with panic disorder.

Conditions

  • Panic Disorder

Interventions

DRUG

Propranolol

Intake of propranolol pill (40 milligram)

DRUG

Placebo

Intake of placebo pill (40 milligram)

OTHER

Carbon dioxide

Inhalation of 35% carbon dioxide

OTHER

Compressed air

Inhalation of air

Sponsors & Collaborators

  • VU University of Amsterdam

    lead OTHER

Principal Investigators

  • Merel Kindt, Prof. dr. · University of Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-09-30
Completion
2019-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631694 on ClinicalTrials.gov